Needham Investment Management LLC Has $13.19 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Needham Investment Management LLC reduced its stake in Thermo Fisher Scientific Inc. by 9.4%, now holding 26,500 shares valued at approximately $13.19 million.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, exceeding estimates, with revenue of $10.86 billion, a 2.9% increase year-over-year.
• The company declared a quarterly dividend of $0.43 per share, set to be paid on October 15th, representing an annualized yield of 0.3%.

Needham Investment Management LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,500 shares of the medical research company's stock after selling 2,750 shares during the period. Thermo Fisher Scientific comprises approximately 1.2% of Needham Investment Management LLC's investment portfolio, making the stock its 28th biggest position. Needham Investment Management LLC's holdings in Thermo Fisher Scientific were worth $13,186,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. GAMMA Investing LLC lifted its stake in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the last quarter. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth $532,360,000. Farallon Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after buying an additional 523,800 shares in the last quarter. Sarasin & Partners LLP acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth $242,991,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Thermo Fisher Scientific by 81.6% during the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock worth $485,479,000 after buying an additional 419,200 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last three months. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Raymond James Financial reiterated an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. UBS Group increased their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO stock traded down $5.38 during mid-day trading on Wednesday, hitting $477.03. The company's stock had a trading volume of 1,442,039 shares, compared to its average volume of 2,409,042. The company's fifty day simple moving average is $463.59 and its 200-day simple moving average is $452.20. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market cap of $180.13 billion, a PE ratio of 27.59, a P/E/G ratio of 2.60 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.